In short
Clinical trials investigating Vinflunine are studying its role in people with advanced urothelial cancer, including locally advanced and metastatic disease. These studies mainly look at how Vinflunine compares with other treatments and whether patients live longer. The trial data focus on adults who have already had prior treatment.
Key points
- Clinical trials investigating Vinflunine are focused on advanced urothelial cancer, including locally advanced, metastatic, and unresectable disease. All of the listed studies are Phase 3 trials, which means they compare treatment options in larger patient groups. The main outcome being measured is overall survival, or how long patients live after treatment begins. Some studies compare Vinflunine with other chemotherapy medicines or with other cancer treatments. The trials mainly involve adults who have already received prior treatment for their cancer.
Trial overview
The trial data show Vinflunine being studied in urothelial cancer, especially when the cancer is locally advanced, metastatic, or unresectable.
All listed studies are Phase 3 trials, which are larger studies used to compare treatment options and measure how well they work in real patient groups.
The studies are completed or authorised, and they mostly compare Vinflunine with other cancer treatments rather than testing it alone.
Who is being studied
The target population is adults with advanced bladder or urinary tract cancer, described in the records as advanced urothelial cancer or urothelial carcinoma.
Some trials focus on people whose cancer has already progressed after earlier treatment, which means the disease got worse even after prior therapy.
One study includes people with locally advanced or metastatic unresectable disease, meaning the cancer cannot be removed by surgery and may have spread.
Another study separates patients into cohorts based on whether they previously received an anti-PD-(L)1 treatment, which is a treatment history detail used to guide the comparison groups.
How the studies are designed
The studies are interventional trials, meaning researchers assign treatments and then watch what happens.
One trial is randomized and open-label, which means patients are placed into treatment groups by chance and both the doctors and patients know which treatment is being given.
Several studies compare Vinflunine with other options such as docetaxel, paclitaxel, pembrolizumab, or investigator’s choice chemotherapy.
In one study, Vinflunine is listed as part of the chemotherapy choices in the comparison arm for patients with prior anti-PD-(L)1 treatment.
Main endpoints and what they mean
The main endpoint in these studies is overall survival, often shortened to OS.
Overall survival means the time from the start of the study treatment, or from randomization in one trial, until death from any cause.
This endpoint is important because it shows whether one treatment helps patients live longer than another treatment.
Key Vinflunine trial settings
NCT04527991 is a Phase 3 randomized open-label study in people with metastatic or locally advanced unresectable urothelial cancer, and it compares sacituzumab govitecan with treatment of physician’s choice.
2023-510296-56-00 is a Phase 3 study in advanced urothelial cancer with selected FGFR changes, and it compares erdafitinib with chemotherapy or pembrolizumab depending on prior treatment history.
In the chemotherapy comparison for Cohort 1, the record names docetaxel or Vinflunine as the chemotherapy options.
2024-517571-20-00 is a Phase 3 study in previously treated locally advanced or metastatic urothelial cancer, comparing enfortumab vedotin with chemotherapy options that include Vinflunine, docetaxel, and paclitaxel.
2024-520014-22-00 is an authorised Phase 3 trial in locally advanced or metastatic urothelial carcinoma, comparing sacituzumab tirumotecan with investigator’s choice nonplatinum chemotherapy, with Vinflunine listed among the options.
What the trial results focus on
These studies are mainly trying to find out whether the tested treatment improves survival compared with the control treatment.
They also show how Vinflunine is being used in research as a chemotherapy choice for advanced urothelial cancer, especially after earlier treatment has not worked well enough.
Because the studies are Phase 3 and include larger patient groups, they are designed to give stronger answers about which treatment approach may be better for these patients.